Tilray Brands Inc banner

Tilray Brands Inc
TSX:TLRY

Watchlist Manager
Tilray Brands Inc Logo
Tilray Brands Inc
TSX:TLRY
Watchlist
Price: 9.4 CAD 1.84%
Market Cap: CA$1.1B

P/B

0.5
Current
20%
More Expensive
vs 3-y average of 0.4

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.5
=
Market Cap
CA$776.2m
/
Total Equity
$1.6B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.5
=
Market Cap
CA$776.2m
/
Total Equity
$1.6B

Valuation Scenarios

Tilray Brands Inc is trading above its 3-year average

If P/B returns to its 3-Year Average (0.4), the stock would be worth CA$7.85 (17% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-17%
Maximum Upside
+631%
Average Upside
249%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 0.5 CA$9.4
0%
3-Year Average 0.4 CA$7.85
-17%
5-Year Average 0.5 CA$8.77
-7%
Industry Average 3.8 CA$68.71
+631%
Country Average 2.5 CA$45.83
+388%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
US
Tilray Brands Inc
TSX:TLRY
803m CAD 0.5 -0.6
US
Eli Lilly and Co
NYSE:LLY
820.3B USD 31 39.9
US
Johnson & Johnson
NYSE:JNJ
542.6B USD 6.8 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.7B GBP 5.9 27.8
CH
Novartis AG
SIX:NOVN
218.9B CHF 5.9 19.6
US
Merck & Co Inc
NYSE:MRK
272.8B USD 5.3 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 6.1 11.5
US
Pfizer Inc
NYSE:PFE
152.3B USD 1.8 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
116.3B USD 6.4 16.7
P/E Multiple
Earnings Growth PEG
US
Tilray Brands Inc
TSX:TLRY
Average P/E: 21.9
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
32%
1.2
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.8
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 10 946 companies
7th percentile
0.7
Low
0 — 1.5
Typical Range
1.5 — 4.8
High
4.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.5
Median 2.5
70th Percentile 4.8
Max 147 580.5

Tilray Brands Inc
Glance View

Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs. Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.

TLRY Intrinsic Value
14.11 CAD
Undervaluation 33%
Intrinsic Value
Price CA$9.4
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett